These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17237266)

  • 1. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
    An J; Rettig MB
    Mol Cancer Ther; 2007 Jan; 6(1):61-9. PubMed ID: 17237266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
    An J; Sun Y; Fisher M; Rettig MB
    Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
    Cascone T; Morelli MP; Morgillo F; Kim WY; Rodolico G; Pepe S; Tortora G; Berrino L; Lee HY; Heymach JV; Ciardiello F
    J Cell Physiol; 2008 Sep; 216(3):698-707. PubMed ID: 18381602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
    Chen YJ; Yeh MH; Yu MC; Wei YL; Chen WS; Chen JY; Shih CY; Tu CY; Chen CH; Hsia TC; Chien PH; Liu SH; Yu YL; Huang WC
    Breast Cancer Res; 2013 Nov; 15(6):R108. PubMed ID: 24216290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism.
    An J; Fisher M; Rettig MB
    Oncogene; 2005 Feb; 24(9):1563-70. PubMed ID: 15608669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.
    Thapa RJ; Chen P; Cheung M; Nogusa S; Pei J; Peri S; Testa JR; Balachandran S
    Mol Cancer Ther; 2013 Aug; 12(8):1568-78. PubMed ID: 23657944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
    Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
    Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
    Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
    Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
    Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.
    Codony-Servat J; Tapia MA; Bosch M; Oliva C; Domingo-Domenech J; Mellado B; Rolfe M; Ross JS; Gascon P; Rovira A; Albanell J
    Mol Cancer Ther; 2006 Mar; 5(3):665-75. PubMed ID: 16546981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
    Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
    Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor.
    Dudek AZ; Lesniewski-Kmak K; Shehadeh NJ; Pandey ON; Franklin M; Kratzke RA; Greeno EW; Kumar P
    Br J Cancer; 2009 May; 100(9):1379-84. PubMed ID: 19401697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
    Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
    Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
    Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
    Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
    Chen Z; Ricker JL; Malhotra PS; Nottingham L; Bagain L; Lee TL; Yeh NT; Van Waes C
    Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
    Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
    J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
    An J; Sun Y; Fisher M; Rettig MB
    Leukemia; 2004 Oct; 18(10):1699-704. PubMed ID: 15343345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.